TAM
KPTI icon

Tocqueville Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Tocqueville Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,000
Closed -$398K – 898
2015
Q4 		$398K Hold
2,000
– – 0.01% 715
2015
Q3 		$316K Buy
2,000
+17
+0.9% +$4.55K ﹤0.01% 799
2015
Q2 		$809K Buy
1,983
+1,030
+108% +$445K 0.01% 610
2015
Q1 		$438K Buy
+953
New +$411K 0.01% 742

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tocqueville Asset Management's KPTI Position: Q1 2016 in Review

Tocqueville Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2016, closing a stake of 2,000 shares — an estimated $398K sold.

Tocqueville Asset Management first reported a position in KPTI in Q1 2015 and held it in 4 quarters. The position peaked at $809K in Q2 2015. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2016.

  • Tocqueville Asset Management reported no remaining Karyopharm Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Tocqueville Asset Management sold 2,000 Karyopharm Therapeutics shares in Q1 2016, an estimated $398K.
  • Tocqueville Asset Management first reported a position in Karyopharm Therapeutics in Q1 2015 and held it in 4 quarters.
  • Tocqueville Asset Management's Karyopharm Therapeutics position peaked at $809K in Q2 2015.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2016.

Based on Tocqueville Asset Management's 13F filing for Q1 2016, filed 29 Apr 2016.